Growth hormone dividend no more? Changchun High-tech profit for the first time in ten years

Changchun High-tech Industries Inc. recently released its 2024 annual report, with the company achieving operating income of 13.466 billion yuan, a decrease of 7.55% compared to the same period last year; and a net profit attributable to shareholders of the listed company of 2.583 billion yuan, a decrease of 43.01% compared to the same period last year. This is the first time in nearly a decade that Changchun High-tech has seen a year-on-year decline in both revenue and net profit. Changchun High-tech's main business is the research, production, and sales of biopharmaceuticals and traditional Chinese medicines, supplemented by real estate development and other businesses, and has formed a development pattern with its subsidiary companies Changchun Jinsai Pharmaceutical Co., Ltd., Changchun Bac Biological Technology Co., Ltd., Jilin Huakang Pharmaceutical Co., Ltd., and Changchun High-tech Real Estate Development Co., Ltd. In 2024, three of these four subsidiaries saw declines in their performance.